Press Releases

Gemelli Biotech and its technologies will be featured in several presentations at Digestive Disease Week® (DDW) 2025. These studies used Trio-Smart®, a diagnostic 3-gas breath test developed and distributed by Gemelli Biotech that uniquely detects hydrogen sulfide, in addition to hydrogen and methane. The studies further validates the accuracy and utility of Trio-Smart and shows the significant cost savings that can result from its use in the diagnosis of SIBO (small intestinal bacterial overgrowth).

Gemelli Biotech announced that new research data generated using its at-home Trio-Smart® three-gas breath test will be presented at Digestive Disease Week® (DDW) 2024, highlighting the test’s validation and clinical correlation with gut microbiome composition. The studies leverage Trio-Smart’s measurement of hydrogen, methane, and hydrogen sulfide to advance understanding of gastrointestinal symptoms and reinforce its utility as a highly validated breath test for chronic intestinal illness.

Gemelli Biotech Corp. (“Gemelli”), a company focused on improving health by providing precision diagnostics for gastrointestinal (GI) diseases, today announced the completion of a $19 million Series A financing. Blue Ox Healthcare Partners (“Blue Ox”), a private equity firm providing growth capital to companies targeting precision health and value-based care, led the investment round, joined by founding investor Cedars-Sinai, along with Carolina Angel Network, CerraCap Ventures, and several family offices.

Los Angeles- and Raleigh-based Gemelli Biotech announced the launch of a novel breath test called trio-smart™ that provides a more complete fermented gas profile of a patient’s microbiome by measuring levels of hydrogen, methane, and hydrogen sulfide after the consumption of a sugar substance (lactulose or glucose). trio-smart™ is a Laboratory Developed Test (LDT) conducted at a CLIA-certified lab.